Obesity / Overweight – Current Treatment – Current Treatment: Physician Insights – GLP-1 receptor agonist products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in recent years. Physicians and patients are increasingly drawn to these therapies because of their established clinical efficacy, convenient dosing, and overall safety profiles. The prescription choices for GLP-1 RA products are often influenced by clinical trial outcomes, real-world evidence, and patient-specific factors, such as comorbidities. However, barriers such as cost and challenging reimbursement often restrict broader adoption. Understanding the prescribing drivers for GLP-1 RA products is crucial for optimizing their use and filling gaps in patient care, as the demand for effective metabolic therapies continues to rise. This content delves deep into the drivers of the GLP-1 RA products market, examining their usage and physicians’ perspectives.
Questions answered
- What is the perception of endocrinologists versus primary care physicians regarding the use of GLP-1 RA products for the treatment of T2D and obesity / overweight?
- How have treatment practices evolved with the emergence of the GLP-1 RA products?
- Which GLP-1 RA products are most preferred vs. most prescribed among specialists for patients with T2D and/or obesity / overweight?
- What factors influence the prescription choices of endocrinologists when prescribing a GLP-1 RA product to their T2D patients who are also obese / overweight?
Content highlights
- Geography: United States
- Primary research: survey of 100 U.S. endocrinologists and primary care physicians / general practitioners
- Key drugs covered: Byetta, Ozempic, Saxenda, Trulicity, Wegovy, Zepbound
- Key insights provided:
- Factors influencing disease management and treatment decisions
- Drivers and constraints of drug selection
- Physician-reported treatment practices
- Physician insight on compliance
- Physician-reported recent / anticipated changes in drug usage or treatment approach
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
